/CTOR
CTOR Stock - Citius Oncology, Inc.
Healthcare|Drug Manufacturers - GeneralNASDAQ
$1.09+1.87%
+$0.02 (+1.87%) • Jan 13
46
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.2
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+450.5%upside
Target: $6.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for CTOR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.08 – $1.10
TARGET (TP)$6.00
STOP LOSS$1.00
RISK/REWARD1:54.6
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta3.10
52W High$6.19
52W Low$0.55
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-23,522,750 | $-20,572,747 | $-12,121,241 | $-4,856,599 | N/A |
| Net Income | $-24,761,369 | $-21,148,747 | $-12,697,241 | $-5,432,599 | $-10,113 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-0.34 | $-0.30 | $-0.19 | $-0.08 | $-0.00 |
Company Overview
Citius Oncology, Inc. focuses on the development of novel targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma. The company is headquartered in New York, New York. Citius Oncology, Inc. operates as a subsidiary of Citius Pharmaceuticals, Inc.
Rating Distribution
Strong Buy
0%
Buy / Outperform
2
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
2 Bullish0 Neutral/Bearish
Price Targets
$5
Average Target
↑ 312.8% Upside
Now
$3
Low
$5
Average
$6
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| September 23rd 2025 | Maxim Group | Upgrade | Buy | $6 |
| November 27th 2024 | Maxim Group | Initiation | Buy | $3 |
Earnings History & Surprises
CTORBeat Rate
40%
Last 5 quarters
Avg Surprise
-3.0%
EPS vs Estimate
Beats / Misses
2/2
1 met exactly
Latest EPS
$-0.06
Q4 2025
EPS Surprise History
Q3 23
No data
Q4 23
No data
Q1 24
No data
Q4 24
+10.3%
$-0.07vs$-0.08
Q1 25
-50.0%
$-0.09vs$-0.06
Q2 25
-22.2%
$-0.11vs$-0.09
Q3 25
+46.7%
$-0.08vs$-0.15
Q4 25
0.0%
$-0.06vs$-0.06
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Dec 23, 2025 | $-0.06 | $-0.06 | 0.0% | = MET |
Q3 2025 | Aug 12, 2025 | $-0.15 | $-0.08 | +46.7% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-0.09 | $-0.11 | -22.2% | ✗ MISS |
Q1 2025 | Feb 14, 2025 | $-0.06 | $-0.09 | -50.0% | ✗ MISS |
Q4 2024 | Dec 27, 2024 | $-0.08 | $-0.07 | +10.3% | ✓ BEAT |
Q1 2024 | Mar 31, 2024 | — | $0.01 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-0.05 | — | — |
Q3 2023 | Sep 30, 2023 | — | $0.00 | — | — |
Q2 2023 | Jun 30, 2023 | — | $0.07 | — | — |
Q1 2023 | Mar 31, 2023 | — | $0.07 | — | — |
Q4 2022 | Dec 31, 2022 | — | $0.04 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.00 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.00 | — | — |
Q2 2021 | Apr 30, 2021 | — | $-0.00 | — | — |
Latest News
CORRECTION: Citius Oncology Is The Subsidiary Of Citius Pharmaceuticals
➖ NeutralBenzinga•Dec 23, 2025, 09:54 PM•Also:
Citius Oncology Q4 EPS $(0.06), Inline
➖ NeutralBenzinga•Dec 23, 2025, 09:39 PM
Citius Pharmaceuticals' Subsidiary Citius Oncology Launches Cancer Immunotherapy, LYMPHIR, In The U.S. In December 2025 For The Treatment Of Adult Patients With Relapsed Or Refractory Stage I-III CTCL After At Least One Prior Systemic Therapy; Co. Raised ~ $61M In Gross Proceeds From Capital Raises
📈 PositiveBenzinga•Dec 23, 2025, 09:36 PM•Also:
Citius Oncology Announces Agreement With Investor For Purchase And Sale Of 1,284,404 Shares At $1.09/Share In Registered Direct Offering; Concurrently Enters Agreement For Purchase And Sale Of 15,229,358 Shares Of Common Stock And Warrants To Purchase Up To 15,229,358 Shares At $1.09/Share And Accompanying Warrant
➖ NeutralBenzinga•Dec 9, 2025, 01:34 PM
Citius Oncology Enters Exclusive Distribution Agreement With Er-Kim For Exclusive LYMPHIR Distribution Across Turkey And Key Gulf Cooperation Council Countries; Agreement Expands Citius Oncology's International Strategy To A Total Of 19 Markets Outside The U.S.
📈 PositiveBenzinga•Dec 4, 2025, 01:40 PM
Citius Oncology rises after U.S. launch of Lymphir as a cancer treatment
📈 PositiveSeeking Alpha•Dec 1, 2025, 07:25 PM
Citius Oncology shares are trading higher after the company announced the commercial launch of LYMPHIR, FDA-Approved IL-2 receptor-directed fusion protein, for the treatment of adult patients with r/r Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy.
📈 PositiveBenzinga•Dec 1, 2025, 07:23 PM
Citius Pharma Subsidiary Announces Commercial Launch Of LYMPHIR, IL-2 Receptor-Directed Fusion Protein For r/r Stage I–III Cutaneous T-Cell Lymphoma Treatment
📈 PositiveBenzinga•Dec 1, 2025, 05:06 PM•Also:
Citius Oncology Collaborates With Verix To Further Leverage Tovana Platform To Support Anticipated Q4 2025 U.S. Commercialization Of FDA Approved LYMPHIR For CTCL Treatment
📈 PositiveBenzinga•Nov 21, 2025, 01:41 PM
Citius Oncology Secures McKesson As Authorized U.S. Distributor For LYMPHIR Ahead Of Q4 2025 Launch
📈 PositiveBenzinga•Oct 20, 2025, 12:39 PM•Also:
Citius Oncology Announced It Has Finalized An Exclusive Agreement With EVERSANA To Support The Q4 2025 U.S. Commercialization Of LYMPHIR
📈 PositiveBenzinga•Oct 16, 2025, 12:52 PM
Citius Oncology Secures Exclusive Distribution With Integris Pharma S.A For LYMPHIR In Greece, Cyprus, And Balkan Nations
📈 PositiveBenzinga•Oct 7, 2025, 12:51 PM
Maxim Group Upgrades Citius Oncology to Buy, Announces $6 Price Target
📈 PositiveBenzinga•Sep 23, 2025, 11:47 AM
Citius Oncology To Raise $9M In Registered Direct Offering Of 5.14M Shares At $1.75 Each, Plus Warrants For 5.14M Shares Exercisable At $1.84
➖ NeutralBenzinga•Sep 9, 2025, 12:47 PM
Citius Oncology and Citius Pharmaceuticals shares are trading higher after announcing the deployment of an AI platform to bolster commercial strategies ahead of the LYMPHIR launch.
📈 PositiveBenzinga•Aug 22, 2025, 01:03 PM•Also:
Citius Oncology Deploys AI Platform To Bolster Commercial Strategy Ahead Of LYMPHIR Launch
📈 PositiveBenzinga•Aug 22, 2025, 12:49 PM
Citius Oncology Beats Fiscal Q3 EPS
📈 PositiveThe Motley Fool•Aug 13, 2025, 01:53 AM
Citius Oncology launches $15M equity and warrant offering; shares down
📉 NegativeSeeking Alpha•Jul 14, 2025, 02:51 PM
Frequently Asked Questions about CTOR
What is CTOR's current stock price?
Citius Oncology, Inc. (CTOR) is currently trading at $1.09 per share. The stock has moved +1.87% today.
What is the analyst price target for CTOR?
The average analyst price target for CTOR is $6.00, based on 1 analyst.
What sector is Citius Oncology, Inc. in?
Citius Oncology, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - General industry. The company is traded on the NASDAQ exchange.
What is CTOR's market cap?
Citius Oncology, Inc. has a market capitalization of $0.09 billion, making it a small-cap company.
Does CTOR pay dividends?
No, Citius Oncology, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACTU
Actuate Therapeutics Inc
$5.52
Mkt Cap: $0.1B
APLT
Applied Therapeutics, Inc.
$0.10
Mkt Cap: $0.0B
FATE
Fate Therapeutics, Inc.
$1.02
Mkt Cap: $0.1B
FBRX
Forte Biosciences, Inc.
$32.49
Mkt Cap: $0.4B
LNSR
LENSAR, Inc.
$11.73
Mkt Cap: $0.1B
MCRB
Seres Therapeutics, Inc.
$15.97
Mkt Cap: $0.1B
OWLT
Owlet, Inc.
$14.20
Mkt Cap: $0.2B
SCLX
Scilex Holding Company
$12.43
Mkt Cap: $0.1B
SPRO
Spero Therapeutics, Inc.
$2.45
Mkt Cap: $0.1B
VOR
Vor Biopharma Inc.
$13.49
Mkt Cap: $0.1B
Explore stocks similar to CTOR for comparison